Related references
Note: Only part of the references are listed.New spiro-oxindole constructed with pyrrolidine/thioxothiazolidin-4-one derivatives: Regioselective synthesis, X-ray crystal structures, Hirshfeld surface analysis, DFT, docking and antimicrobial studies
Assem Barakat et al.
JOURNAL OF MOLECULAR STRUCTURE (2018)
Regio- and stereoselective synthesis of new spirooxindoles via 1,3-dipolar cycloaddition reaction: Anticancer and molecular docking studies
Gehad Lofty et al.
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY (2018)
Current Trends towards the Synthesis of Bioactive Heterocycles and Natural Products Using 1,3-Dipolar Cycloadditions (1,3-DC) with Azomethine Ylides
H. Ali Dondas et al.
SYNTHESIS-STUTTGART (2017)
Synthesis of new spirooxindole-pyrrolothiazole derivatives: Anti-cancer activity and molecular docking
Gehad Lotfy et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Synthesis, docking, cytotoxicity, and LTA4H inhibitory activity of new gingerol derivatives as potential colorectal cancer therapy
Mai H. El-Naggar et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
2-Indolinone a versatile scaffold for treatment of cancer: a patent review (2008-2014)
Alberto Leoni et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2016)
Molecular diversity of spirooxindoles. Synthesis and biological activity
Tetyana L. Pavlovska et al.
MOLECULAR DIVERSITY (2016)
Spirooxindoles: Promising scaffolds for anticancer agents
Bin Yu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Discovery of a Small Molecule MDM2 Inhibitor (AMG 232) for Treating Cancer
Yosup Rew et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Recent advances in the synthesis of biologically active spirooxindoles
Maria M. M. Santos
TETRAHEDRON (2014)
A facile synthesis, anti-inflammatory and analgesic activity of isoxazolyl-2,3-dihydrospiro[benzo[f]isoindole-1,3′-indoline]-2′,4,9-triones
E. Rajanarendar et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
A Potent Small-Molecule Inhibitor of the MDM2-p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice
Yujun Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Diastereomeric Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors
Yujun Zhao et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
N-Heterocyclic Carbene-Catalyzed Homoenolate Additions with N-Aryl Ketimines as Electrophiles: Efficient Synthesis of Spirocyclic γ-Lactam Oxindoles
Bo Zhang et al.
CHEMISTRY-A EUROPEAN JOURNAL (2012)
In vitro and in vivo study of cucurbitacins-type triterpene glucoside from Citrullus colocynthis growing in Saudi Arabia against hepatocellular carcinoma
Seif-Eldin N. Ayyad et al.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY (2012)
Small molecule agents targeting the p53-MDM2 pathway for cancer therapy
Weisi Wang et al.
MEDICINAL RESEARCH REVIEWS (2012)
FRED Pose Prediction and Virtual Screening Accuracy
Mark McGann
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
Antimycobacterial activity of spirooxindolo-pyrrolidine, pyrrolizine and pyrrolothiazole hybrids obtained by a three-component regio- and stereoselective 1,3-dipolar cycloaddition
Stephen Michael Rajesh et al.
MEDCHEMCOMM (2011)
Substituted spiro [2.3′] oxindolespiro [3.2]-5,6-dimethoxy-indane-1-one-pyrrolidine analogue as inhibitors of acetylcholinesterase
Mohamed Ashraf Ali et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Targeting cancer with phosphodiesterase inhibitors
Rajkumar Savai et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database
Paul C. D. Hawkins et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2010)
Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay
Christophe Marchand et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy
Thomas S. Dexheimer et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2008)
Lessons in molecular recognition. 2. Assessing and improving cross-docking accuracy
Jeffrey J. Sutherland et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2007)
Overview of PDEs and their regulation
Kenji Omori et al.
CIRCULATION RESEARCH (2007)
Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents
C Lugnier
PHARMACOLOGY & THERAPEUTICS (2006)
Phosphodiesterase inhibitors as anti-cancer drugs
L Hirsh et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Structural basis for the activity of drugs that inhibit phosphodiesterases
GL Card et al.
STRUCTURE (2004)
Potency, selectivity, and consequences of nonselectivity of PDE inhibition
E Bischoff
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2004)
Phenolic glycosides from Symplocos racemosa:: natural inhibitors of phosphodiesterase I
VU Ahmad et al.
PHYTOCHEMISTRY (2003)
Crystal structure of a transition state mimic for Tdp1 assembled from vanadate, DNA, and a topoisomerase I-derived peptide
DR Davies et al.
CHEMISTRY & BIOLOGY (2003)
The crystal structure of human tyrosyl-DNA phosphodiesterase, Tdp1
DR Davies et al.
STRUCTURE (2002)
Immune modulatory potentials of antineoplaston A-10 in breast cancer patients
F Badria et al.
CANCER LETTERS (2000)
Potential utility of antineoplaston A-10 levels in breast cancer
F Badria et al.
CANCER LETTERS (2000)
Share Paper
